This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma or Patients Treated With Rituximab-CHOP or Rituximab-CVP
and you are
between 15 and 90
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy. Rituximab monoclonal antibody targeting CD20 induces B-cell depletion resulting in prolonged immune suppression. This leads to frequent reactivation of patients with a previous history of exposure to HBV or HBV carrier. We collect the clinical features and laboratory findings of patients satisfied the inclusion criteria as follows. 1. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) or \ follicular B-cell lymphoma (FL). 2. Patients who had received at least two cycles of rituximab-CHOP or rituximab-CVP as a primary treatment 3. Patients with a history of previous exposure to HBV - HBV surface antigen (HBs Ag) positive Or - HBV core antibody (IgG anti-HBc antibody) positive Then, we compare the HBV reactivation group with the control group (HBV reactivation does not happen) to find factors influencing HBV reactivation.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01311232. The sponsor of the trial is Samsung Medical Center and it is looking for 600 volunteers for the current phase.
Official trial title:
Hepatitis B Virus Reactivation in Asian Patients Treated With Rituximab-containing Treatment